According to the government, with a total of 34 million doses available in 2022, the Swiss population of 8.7 million people is more than covered, even if another wave of infections strikes.
For this reason, it will make 15 million vaccines available to the Covax initiative.
Last year, Switzerland donated four million doses from AstraZeneca to this mechanism and postponed the purchase of one million Moderna injections so that Covax could benefit from the freed-up production capacity.
The solidarity action comes as the vaccination rate in this country exceeds 70 percent.
Covax emerged in 2020 under the aegis of the WHO Global Alliance for Vaccines and Immunization to become an unprecedented multilateral response to an unprecedented health crisis.
Two years into the pandemic, universal access to immunogens remains a pending task for the poorest countries, and the call for the release of patents on these products is far from being a reality, with manufacturing laboratories making a huge financial profit from the situation.